Literature DB >> 26779832

Considerations in producing preferentially reduced half-antibody fragments.

Asta Makaraviciute1, Carolyn D Jackson2, Paul A Millner3, Almira Ramanaviciene4.   

Abstract

Half-antibody fragments are a promising reagent for biosensing, drug-delivery and labeling applications, since exposure of the free thiol group in the Fc hinge region allows oriented reaction. Despite the structural variations among the molecules of different IgG subclasses and those obtained from different hosts, only generalized preferential antibody reduction protocols are currently available. Preferential reduction of polyclonal sheep anti-digoxin, rabbit anti-Escherichia coli and anti-myoglobin class IgG antibodies to half-antibody fragments has been investigated. A mild reductant 2-mercaptoethylamine (2-MEA) and a slightly stronger reductant tris(2-carboxyethyl)phosphine (TCEP) were used and the fragments obtained were quantitatively determined by SDS-PAGE analysis. It has been shown that the yields of half-antibody fragments could be increased by lowering the pH of the reduction mixtures. However, antibody susceptibility to the reductants varied. At pH4.5 the highest yield of sheep anti-digoxin IgG half-antibody fragments was obtained with 1M 2-MEA. Conversely, rabbit IgG half-antibody fragments could only be obtained with the stronger reductant TCEP. Preferential reduction of rabbit anti-myoglobin IgG antibodies was optimized and the highest half-antibody yield was obtained with 35 mM TCEP. Finally, it has been demonstrated that produced anti-myoglobin half-IgG fragments retained their binding activity.
Copyright © 2016 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  2-mercaptoethylamine; Half-antibody fragments; Hinge region thiols; Reduced antibody; Tris(2-carboxyethyl)phosphine

Mesh:

Substances:

Year:  2016        PMID: 26779832     DOI: 10.1016/j.jim.2016.01.001

Source DB:  PubMed          Journal:  J Immunol Methods        ISSN: 0022-1759            Impact factor:   2.303


  8 in total

1.  GingisKHAN™ protease cleavage allows a high-throughput antibody to Fab conversion enabling direct functional assessment during lead identification of human monoclonal and bispecific IgG1 antibodies.

Authors:  Jörg Moelleken; Manuel Endesfelder; Christian Gassner; Sabine Lingke; Simone Tomaschek; Oksana Tyshchuk; Stefan Lorenz; Ulrike Reiff; Michael Mølhøj
Journal:  MAbs       Date:  2017-08-14       Impact factor: 5.857

2.  Inter-laboratory study of an optimised peptide mapping workflow using automated trypsin digestion for monitoring monoclonal antibody product quality attributes.

Authors:  Silvia Millán-Martín; Craig Jakes; Sara Carillo; Tom Buchanan; Marc Guender; Dan Bach Kristensen; Trine Meiborg Sloth; Martin Ørgaard; Ken Cook; Jonathan Bones
Journal:  Anal Bioanal Chem       Date:  2020-07-25       Impact factor: 4.142

3.  Engineering Modular Half-Antibody Conjugated Nanoparticles for Targeting CD44v6-Expressing Cancer Cells.

Authors:  Bianca N Lourenço; Rúben F Pereira; Cristina C Barrias; Claudia Fischbach; Carla Oliveira; Pedro L Granja
Journal:  Nanomaterials (Basel)       Date:  2021-01-23       Impact factor: 5.076

4.  Monovalent antibody-conjugated lipid-polymer nanohybrids for active targeting to desmoglein 3 of keratinocytes to attenuate psoriasiform inflammation.

Authors:  Zih-Chan Lin; Tsong-Long Hwang; Tse-Hung Huang; Kohei Tahara; Jiří Trousil; Jia-You Fang
Journal:  Theranostics       Date:  2021-03-04       Impact factor: 11.556

5.  89Zr Immuno-PET Imaging of Tumor PD-1 Reveals That PMA Upregulates Lymphoma PD-1 through NFκB and JNK Signaling.

Authors:  Kyung-Ho Jung; Jin Hee Lee; Mina Kim; Young Seok Cho; Kyung-Han Lee
Journal:  Mol Imaging       Date:  2022-02-12       Impact factor: 3.250

6.  89Zr-Labeled Anti-PD-L1 Antibody PET Monitors Gemcitabine Therapy-Induced Modulation of Tumor PD-L1 Expression.

Authors:  Kyung-Ho Jung; Jin Won Park; Jin Hee Lee; Seung Hwan Moon; Young Seok Cho; Kyung-Han Lee
Journal:  J Nucl Med       Date:  2020-09-11       Impact factor: 10.057

7.  Site-specific chemical conjugation of human Fas ligand extracellular domain using trans-cyclooctene - methyltetrazine reactions.

Authors:  Michiro Muraki; Kiyonori Hirota
Journal:  BMC Biotechnol       Date:  2017-07-03       Impact factor: 2.563

8.  Celecoxib-Induced Modulation of Colon Cancer CD133 Expression Occurs through AKT Inhibition and Is Monitored by 89Zr Immuno-PET.

Authors:  Kyung-Ho Jung; Jin Hee Lee; Mina Kim; Eun Ji Lee; Young Seok Cho; Kyung-Han Lee
Journal:  Mol Imaging       Date:  2022-01-07       Impact factor: 4.488

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.